# A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

> **NCT00211185** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 49 (actual)

## Conditions studied

- Lymphoma, T-Cell, Peripheral

## Interventions

- **DRUG:** Denileukin diftitox
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **OTHER:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT00211185
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03-14
- **Primary completion:** 2008-08
- **Final completion:** 2009-12-23
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2020-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00211185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00211185, "A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00211185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*